儿童神经母细胞瘤行靶向治疗的研究进展  

Research Progress of Targeted Therapy for Neuroblastoma in Children

作　　者：杨宁 魏婷 徐嫚 曾庆威 董英强 Yang Ning;Wei Ting;Xu Man(Heilongjiang Hospital,Beijing Children’s Hospital,Harbin,Heilongjiang,150010,China)

机构地区：[1]北京儿童医院黑龙江医院,黑龙江哈尔滨150010

出　　处：《黑龙江医学》2024年第14期1779-1781,1785,共4页Heilongjiang Medical Journal

摘　　要：神经母细胞瘤是一个恶性程度相对较大的一类病症,现今医学上用来诊断儿童成长期甚至是恢复疾病的疗效较差。神经母细胞瘤肿瘤细胞具有大量可变和异质性的组织化学和基因变化,因此必须进行个体化和靶向治疗,以引导癌症消失。随着现今医学科技水平的日益发展,神经母细胞瘤分子在生理学方面的认识水平也日益提高,这导致靶向用药临床应用的研究也进一步深入,从而在儿童神经母细胞瘤方向上也获得了一些发展。本研究将对目前已开展临床试验的靶向治疗技术、间位腆代苄胍、抗肿瘤的靶向治疗、血管内皮生长因子疗法以及MYCN基因靶向治疗技术等五个领域的研究进展加以整理,希望为当前学术界在这个方面的探索以及发展相应的临床研究提供借鉴。Neuroblastoma is a relatively large malignant disease,which is currently used to diagnose children’s long growth period or even poor recovery disease effect.The tumor cells have substantial variable and heterogeneous histochemical and genetic changes,and therefore individualized and targeted therapies should be undergone to guide cancer disappearance.With the increasing development of today’s society,the understanding level of molecular physiology is also increasing,which leads to the research on the clinical application of targeted drugs,thus some progress has also been achieved in the direction of neuroblastoma in children.The study will review the research progress in targeted therapy technology,mesobenidine,anti-tumor targeted therapy,vascular endothelial growth factor therapy and MYCN gene targeted therapy technology,which have been carried out clinical trials at present,so as to provide reference for the current academic exploration in this area and the development of corresponding clinical research.

关 键 词：神经母细胞瘤 儿科用药 靶向治疗 研究进展 

分 类 号：R739.4[医药卫生—肿瘤]